Research Topics
| Julie R ParkSummaryAffiliation: University of Washington Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Children's Oncology Group's 2013 blueprint for research: NeuroblastomaJulie R Park
Seattle Children s Hospital, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, Washington
Pediatr Blood Cancer 60:985-93. 2013..Pediatr Blood Cancer 2013; 60: 985-993. © 2013 Wiley Periodicals, Inc...
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyJulie R Park
Seattle Children s Hospital, 4800 Sandpoint Way NE, Mailstop B6553, Seattle, WA 98105, USA
J Clin Oncol 29:4351-7. 2011..To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB)...- Neuroblastoma: biology, prognosis, and treatmentJulie R Park
Division of Hematology and Oncology, University of Washington School of Medicine and Seattle Children s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105 0371, USA
Hematol Oncol Clin North Am 24:65-86. 2010.... - Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park
Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
Pediatr Blood Cancer 52:44-50. 2009..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial... - Neuroblastoma: biology, prognosis, and treatmentJulie R Park
Division of Hematology and Oncology, University of Washington School of Medicine and Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
Pediatr Clin North Am 55:97-120, x. 2008.... 
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapseBlythe Thomson
Seattle Children s Hospital and Regional Medical Center, Seattle, Washington, USA
Pediatr Blood Cancer 43:571-9. 2004..The ability to achieve a durable second remission is complicated by toxicity and resistant disease. We report a novel combination of chemotherapy for relapsed pediatric ALL...- Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantationThomas G Gross
Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA
J Clin Oncol 23:6481-8. 2005.... - Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastomaScott M Bradfield
Department of Pediatric Hematology/Oncology, Children's Hospital and Regional Medical Center, Seattle, Washington 98105-5371, USA
Cancer 100:1268-75. 2004..CONCLUSIONS: Post-HSCT, fractionated XRT to 2100 cGy was a tolerable and effective treatment for patients with high-risk NB, and minimal recurrences were observed at designated XRT sites... - Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoBrianne S Raccor
Department of Pharmacy, University of Washington, Seattle, WA 98195 7610, USA
Drug Metab Dispos 40:54-63. 2012..Concomitant chemotherapy agents did not influence 4HCY formation in vitro. We conclude that CYP2B6 genotype is not consistently related to 4HCY formation in vitro or in vivo... - Influenza-associated morbidity in children with cancerSarah K Tasian
Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
Pediatr Blood Cancer 50:983-7. 2008..The clinical impact of influenza in children undergoing therapy for cancer is not well-described in the literature... - High-risk neuroblastoma: a therapy in evolutionAbraham Fong
Seattle Children s Hospital and University of Washington, Department of Pediatrics, Seattle, Washington 98105, USA
Pediatr Hematol Oncol 26:539-48. 2009..These novel therapies are likely to pose a whole new set of challenges and questions and emphasize the need for continued enrollment of patients in therapeutic studies... - Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemiaDouglas S Hawkins
Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
Clin Cancer Res 10:5335-41. 2004.... - Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupJeannine S McCune
Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195 7630, USA
J Clin Pharmacol 49:88-102. 2009.... - Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastomaJulie R Park
Department of Pediatric Hematology Oncology, Children s Hospital and Medical Center, Seattle, Washington, USA
Mol Ther 15:825-33. 2007..This first-in-humans pilot study sets the stage for clinical trials employing adoptive transfer in the context of minimal residual disease... - Prolonged survival after invasive aspergillosis: a single-institution review of 11 casesJessica A Wright
Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98105 0371, USA
J Pediatr Hematol Oncol 25:286-91. 2003..Case series of IA in the pediatric oncology population are limited but generally report poor overall survival... - Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patientsJulie R Park
Pediatric Hematology Oncology, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington, USA
Med Pediatr Oncol 40:93-8. 2003..Outpatient empiric antibiotic therapy can be safely administered to a subset of febrile neutropenic patients at low risk for clinical complications...
Research Grants
- Novel Therapies for High-Risk NeuroblastomaJulie Park; Fiscal Year: 2006..abstract_text> ..